{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018005","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.851691+00:00","generated_at":"2026-06-23T17:42:37.056689+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Finch Therapeutics cuts 37% workforce, suspends FIN-211 trial after Takeda deal ends","bullets":["Reduces workforce by 50 employees (~37% of staff) to cut costs.","Suspends initiation of Phase 1 trial for FIN-211 (autism candidate).","Estimates $1.6M in severance and related expenses; charges expected in H2 2022.","Action follows termination of Takeda IBD collaboration and ongoing strategic review.","Restructuring substantially complete by Q4 2022; cash runway update to come."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018005","json":"https://secwatch.observer/filing/0000950170-22-018005.json","markdown":"https://secwatch.observer/filing/0000950170-22-018005.md","text":"https://secwatch.observer/filing/0000950170-22-018005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022018005/0000950170-22-018005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022018005/fnch-20220901.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T17:42:37.056689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}